Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.58 |
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27436076 | 1.00 | NOD1 (0.58) | NOD1GLP1REPHX2FOLH1SLC6A5 | |
| SCHEMBL23365799 | 1.00 | NOD1 (0.58) | NOD1GLP1REPHX2FOLH1SLC6A5 | |
| SCHEMBL20414814 | 1.00 | NOD1 (0.58) | NOD1GLP1REPHX2FOLH1SLC6A5 | |
| SCHEMBL16259357 | 0.90 | NOD1 (0.71) | NOD1GLP1REPHX2SLC6A5 | |
| SCHEMBL20162097 | 0.90 | NOD1 (0.71) | NOD1GLP1REPHX2SLC6A5 | |
| SCHEMBL16259359 | 0.90 | NOD1 (0.71) | NOD1GLP1REPHX2SLC6A5 | |
| SCHEMBL16259353 | 0.90 | NOD1 (0.71) | NOD1GLP1REPHX2SLC6A5 | |
| SCHEMBL16259355 | 0.90 | NOD1 (0.71) | NOD1GLP1REPHX2SLC6A5 | |
| SCHEMBL27436101 | 0.89 | TLR2 (0.52) | NOD1GLP1REPHX2 | |
| SCHEMBL23365798 | 0.89 | TLR2 (0.52) | NOD1GLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3079722-B1 | METHOD FOR THIOETHER CONJUGATION OF PROTEINS | NOVO NORDISK HEALTHCARE AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| EP-2981282-B1 | GROWTH HORMONE COMPOUND FORMULATION | NOVO NORDISK HEALTHCARE AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| EP-2525834-B1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-17 | — | — | EP | disclosed |